EraCal Therapeutics Collaborates with Novo Nordisk to Develop and Commercialize its Small Molecule Program
Shots:
- EraCal Therapeutics and Novo Nordisk have signed a collaboration and license agreement for the development and commercialization of EraCal’s oral, small-molecule program
- Under the terms of the agreement, EraCal will obtain upfront, development, and commercial milestones of up to $256.29M (€235M) along with royalties on sales while Novo Nordisk receives the exclusive development and commercialization rights of the program
- The discovery of the program has been carried out with EraCal’s platform technology which aims to target a novel mechanism of action controlling appetite and body weight to treat obesity
Ref: EraCal Therapeutics | Image: Novo Nordisk
Related News:- Dewpoint Therapeutics Collaborates with Evotec to Accelerate its Oncology Pipeline
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
